Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in...

Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual
Growth in the HIV Drug Market Through 2013

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the
World's Major Markets, According to a New Report from Decision Resources

WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms for pharmaceutical and healthcare issues,
finds that sales of antiretroviral agents will drive substantial six percent
annual growth in the HIV drug market through 2013 but significant generic
erosion of key therapies thereafter will slow annual growth to less than two
percent from 2013 to 2018 in the United States, France, Germany, Italy, Spain,
the United Kingdom and Japan.

The new Pharmacor report entitled Human Immunodeficiency Virus finds that
continued increase in the uptake of Bristol-Myers Squibb/Gilead's Atripla will
drive the agent to garner the highest sales of any antiretroviral in 2013.
However, from 2013 to 2018, Gilead's Quad will make significant inroads in the
HIV market and by 2018 will become the highest-selling antiretroviral drug in
the world's major markets, according to the report. Quad will combine
favorable safety and efficacy with the dosing convenience of a single daily
pill regimen, making it an ideal product for treatment-naive patients.

"The largest commercial opportunities in the HIV market lie in the development
of therapies with enhanced convenience, such as co-formulations that minimize
the number of pills and frequency of dosing, especially safe and effective
therapies that target treatment-naive patients -- the most lucrative segment
of the market," said Decision Resources Analyst Jose Avalos, Ph.D. "In
addition, agents with reduced long-term toxicities can differentiate
themselves in this crowded market."

The report also finds that two novel classes of antiretroviral agents -- the
integrase inhibitors and CCR5 antagonists -- have been received with different
levels of enthusiasm among interviewed experts and prescribers. Merck's
Isentress, the first integrase inhibitor on the market, has been received with
great enthusiasm by physicians and patients because of its efficacy, safety,
and simple dosing. In contrast, Pfizer's Selzentry, the first-in-class CCR5
antagonist, has experienced significant obstacles that include its limited
patient eligibility and the lengthy tropism test required for its
prescription. The landscape for CCR5 antagonists is expected to improve,
however, once better tropism tests and improved protocols are established.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:

Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com